BB Biotech AG (BBZA.DE)
EUR 39.05
(0.77%)
EUR 39.05
(0.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 304.39 Million CHF | -15.69% |
| 2022 | 361.05 Million CHF | 2.52% |
| 2021 | 352.16 Million CHF | 526.81% |
| 2020 | 56.18 Million CHF | -52.9% |
| 2019 | 119.29 Million CHF | -26.78% |
| 2018 | 162.92 Million CHF | 93.34% |
| 2017 | 84.27 Million CHF | -56.73% |
| 2016 | 194.77 Million CHF | 40.18% |
| 2015 | 138.94 Million CHF | 560.62% |
| 2014 | 21.03 Million CHF | -54.58% |
| 2013 | 46.3 Million CHF | -60.13% |
| 2012 | 116.14 Million CHF | 0.0% |
| 2011 | - CHF | 0.0% |
| 2010 | - CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 100.0% |
| 2007 | -10.87 Million CHF | 10.81% |
| 2006 | -12.19 Million CHF | -945.54% |
| 2005 | -1.16 Million CHF | 0.0% |
| 2004 | - CHF | 0.0% |
| 2003 | - CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 319.08 Million CHF | -7.32% |
| 2024 Q1 | 344.29 Million CHF | 13.11% |
| 2023 Q3 | 301.77 Million CHF | -1.89% |
| 2023 Q4 | 304.39 Million CHF | 0.87% |
| 2023 FY | 304.39 Million CHF | -15.69% |
| 2023 Q2 | 307.6 Million CHF | -2.27% |
| 2023 Q1 | 314.74 Million CHF | -12.83% |
| 2022 Q1 | 353.36 Million CHF | 0.34% |
| 2022 Q2 | 324.27 Million CHF | -8.23% |
| 2022 Q3 | 299.97 Million CHF | -7.49% |
| 2022 Q4 | 361.05 Million CHF | 20.36% |
| 2022 FY | 361.05 Million CHF | 2.52% |
| 2021 Q2 | 296.82 Million CHF | -14.23% |
| 2021 Q4 | 352.16 Million CHF | 43.03% |
| 2021 Q3 | 246.22 Million CHF | -17.05% |
| 2021 Q1 | 346.08 Million CHF | 515.99% |
| 2021 FY | 352.16 Million CHF | 526.81% |
| 2020 Q2 | 166.71 Million CHF | -48.82% |
| 2020 Q1 | 325.72 Million CHF | 173.04% |
| 2020 Q3 | 230.11 Million CHF | 38.03% |
| 2020 Q4 | 56.18 Million CHF | -75.58% |
| 2020 FY | 56.18 Million CHF | -52.9% |
| 2019 Q2 | 361.2 Million CHF | -1.47% |
| 2019 Q1 | 366.59 Million CHF | 125.0% |
| 2019 FY | 119.29 Million CHF | -26.78% |
| 2019 Q4 | 119.29 Million CHF | 0.0% |
| 2018 Q3 | 314.82 Million CHF | -4.66% |
| 2018 FY | 162.92 Million CHF | 93.34% |
| 2018 Q2 | 330.2 Million CHF | 13.6% |
| 2018 Q1 | 290.68 Million CHF | 244.94% |
| 2018 Q4 | 162.92 Million CHF | -48.25% |
| 2017 Q2 | -23 Million CHF | -107.57% |
| 2017 Q1 | 303.79 Million CHF | 55.98% |
| 2017 FY | 84.27 Million CHF | -56.73% |
| 2017 Q4 | 84.27 Million CHF | 2003.59% |
| 2017 Q3 | 4 Million CHF | 117.41% |
| 2016 FY | 194.77 Million CHF | 40.18% |
| 2016 Q3 | 210.5 Million CHF | -36.54% |
| 2016 Q1 | 333.78 Million CHF | 140.23% |
| 2016 Q2 | 331.72 Million CHF | -0.62% |
| 2016 Q4 | 194.77 Million CHF | -7.48% |
| 2015 Q3 | 56.23 Million CHF | 142.31% |
| 2015 Q4 | 138.94 Million CHF | 147.05% |
| 2015 FY | 138.94 Million CHF | 560.62% |
| 2015 Q1 | 18.77 Million CHF | -10.73% |
| 2015 Q2 | -132.91 Million CHF | -807.9% |
| 2014 Q3 | 129.11 Million CHF | -10.32% |
| 2014 FY | 21.03 Million CHF | -54.58% |
| 2014 Q4 | 21.03 Million CHF | -83.71% |
| 2014 Q2 | 143.97 Million CHF | -2.66% |
| 2014 Q1 | 147.91 Million CHF | 219.46% |
| 2013 Q4 | 46.3 Million CHF | -54.88% |
| 2013 FY | 46.3 Million CHF | -60.13% |
| 2013 Q1 | 114.11 Million CHF | -1.75% |
| 2013 Q3 | 102.62 Million CHF | 20.19% |
| 2013 Q2 | 85.38 Million CHF | -25.18% |
| 2012 Q4 | 116.14 Million CHF | 0.0% |
| 2012 FY | 116.14 Million CHF | 0.0% |
| 2012 Q1 | - CHF | 0.0% |
| 2012 Q2 | 144.06 Million CHF | 0.0% |
| 2012 Q3 | - CHF | -100.0% |
| 2011 FY | - CHF | 0.0% |
| 2011 Q2 | 157.7 Million CHF | 18.71% |
| 2011 Q3 | - CHF | -100.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 Q1 | 132.85 Million CHF | 0.0% |
| 2010 FY | - CHF | 0.0% |
| 2010 Q2 | - CHF | 0.0% |
| 2010 Q1 | - CHF | 0.0% |
| 2010 Q4 | - CHF | 0.0% |
| 2010 Q3 | - CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 100.0% |
| 2007 FY | -10.87 Million CHF | 10.81% |
| 2006 FY | -12.19 Million CHF | -945.54% |
| 2005 FY | -1.16 Million CHF | 0.0% |
| 2004 FY | - CHF | 0.0% |
| 2003 FY | - CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 102.66% |
| CureVac N.V. | -360.92 Million EUR | 184.338% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 46.718% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 46.718% |
| BRAIN Biotech AG | -693 Thousand EUR | 44024.82% |
| Formycon AG | 2.45 Million EUR | -12319.38% |
| Heidelberg Pharma AG | -37.6 Million EUR | 909.409% |
| Medigene AG | -5.72 Million EUR | 5417.942% |